Track market-moving stories before they get noisy

Key Takeaways HII secured a $56 million AUKUS contract, potentially rising to $91 million.HII will support submarine design, technology integration and supply-chain development.HII's nuclear shipbuilding expertise could support long-term growth under AUKUS. Huntington Ingalls Industries (HII - Free Report) is positioned to benefit from growing cooperation among the United States, the United Kingdom and Australia to strengthen undersea defense capabilities. The AUKUS partnership is creating opportunities for submarine design, engineering, technology development and supply-chain cooperation among the three nations.

HII’s Newport News Shipbuilding division plays an important role in these efforts, drawing on its experience in designing and building nuclear-powered submarines. On Oct. 13, 2026, the company announced a $56 million U.S. Navy contract for shipbuilding engineering and design support for AUKUS. An option could increase the contract’s cumulative value to $91 million.

The work includes technology integration, engineering, supply-chain development, workforce support and digital transformation. HII engineers and designers will also contribute to the design of the SSN-AUKUS nuclear-powered submarine, which is planned for construction in the United Kingdom and Australia.

Beyond this contract, HII is supporting the development of an allied submarine industrial base. Its Mission Technologies division helps Australian suppliers qualify to participate in the U.S. submarine supply chain, creating opportunities for broader industrial cooperation.

The AUKUS partnership could provide long-term work across submarine design, production support and supplier development. HII’s nuclear shipbuilding expertise and involvement across multiple parts of the initiative position it to benefit as the participating countries advance their submarine capabilities. Execution, workforce availability and supply-chain readiness will remain key to translating these opportunities into sustained growth.

Defense Stocks to Keep on the RadarGrowing investment in nuclear-powered submarines and allied naval capabilities could also benefit other defense contractors.

General Dynamics (GD - Free Report) : General Dynamics’ Electric Boat business builds Virginia-class and Columbia-class submarines for the U.S. Navy, supporting demand for nuclear submarine construction and related engineering.

BAE Systems (BAESY - Free Report) : BAE Systems is a major supplier to the U.K. defense sector and is developing advanced submarine capabilities, positioning it to participate in the United Kingdom’s broader naval modernization efforts.

The Zacks Rundown for HIIShares of HII have lost 4.5% in the past year compared with the industry’s 17.9% decline.

Image Source: Zacks Investment Research

The company's shares are trading at a discount on a relative basis, with its forward 12-month Price/Sales being 0.75X compared with its industry’s average of 2.11X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for HII’s 2026 and 2027 earnings has moved north over the past 60 days.

Image Source: Zacks Investment Research

HII stock currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

An $850 million zero-interest convertible debt offering and a concurrent share issuance sent Cipher Digital (CIFR -3.79%) down 25.7% this week, according to data provided by S&P Global Market Intelligence.

Cipher Digital stock changed hands at $10.04 as of the close on Thursday, Oct. 15, down 25.7% from Friday, Oct. 9's close through Thursday, Oct. 15's close. Over the same period, the S&P 500 (^GSPC -0.09%) fell 0.3%, and the Nasdaq-100 was down 1.8%.

$9.66-$0.38 (-3.79%)

NASDAQ · As of 10:18 AM ET 10/16/26

Convertible debt and dilution worries spark a sell-offManagement announced a private offering of $850 million in 0.00% convertible senior notes due 2032, with an option for initial buyers to purchase up to an additional $150 million. Convertible senior notes are zero-interest debt obligations that investors can later exchange for equity, trading lower interest expenses for potential stock dilution. Concurrently, the company agreed to exchange $165.9 million of its 1.75% convertible notes due 2030 for approximately 40.7 million common shares, swapping debt obligations for immediate share dilution. The stock sits down 66.7% (as of the close on Thursday, Oct. 15) from its 52-week high of $30.14.

Cipher Digital operates industrial-scale data centers and leases high-performance computing infrastructure and Bitcoin mining sites to technology and digital asset clients. The company plans to use the net proceeds to fund capital expenditures for its Barber Lake data center expansion in Texas, where it absorbs the first $359.3 million in construction cost overruns. Adding high-performance computing capacity diversifies revenue away from volatile crypto mining toward fixed-rate corporate leases.

Cipher Digital trades at a price-to-sales (P/S) ratio of 21, sitting well above the peer average of 5.4, with Marathon Digital Holdings at 4.2, Riot Platforms at 8.4, and CleanSpark at 3.5, a premium investors will accept only if its high-performance computing conversion yields reliable rental revenue. This week's $850 million convertible debt offering sharpens dilution risks while confirming that Cipher's pivot into high-performance computing infrastructure requires capital-intensive site expansion.

What to watch next for Cipher DigitalInvestors should look toward the company's next earnings report for updated construction timelines and lease revenue metrics. The key operational milestone to monitor is whether initial rent payments from the expanded Barber Lake and Black Pearl campuses begin flowing on schedule to offset rising debt loads.

Is Cipher Digital Stock a Buy?Cipher Digital is still on track for long-term growth. The stock fell due to the additional shares to be issued as part of the convertible note offering, which dilutes shareholders' investment. The risk of owning the stock to finance the data center build-out is share dilution, but this is short-term pain for long-term gain.

The offering comes after it extended the contracted lease for its Barber Lake data center in Colorado City, Texas, from 10 to 20 years. This extension means more revenue, increasing the facility's total contracted revenue from $3.8 billion to over $9 billion.

In light of the additional $5.2 billion in revenue Cipher will generate under the new agreement, the dilution from the recent convertible note offering appears very minor. Investors can look at the sell-off as a buying opportunity.

Next catalyst to watch: The company's Q3 2026 earnings release, likely in November, where investors will look for additional data center development news.

Risk note: The primary risk stems from share dilution or cost overruns on debt-funded data center construction.

Bull points:

The 20-year Barber Lake lease amendment expands contracted long-term revenue commitment to over $9 billion.Zero-coupon convertible notes allow the company to raise $850 million without incurring immediate cash interest expenses.Transitioning capacity to high-performance computing provides predictable, long-term rental income distinct from Bitcoin price swings.Bear points:

Exchanging notes for 40.7 million common shares causes immediate equity dilution for existing shareholders.Cipher must absorb the first $359.3 million in Barber Lake construction cost overruns, increasing execution risk.The company's P/S ratio of 21.8 represents a steep premium over crypto mining peers.

Casey's General Stores (CASY +1.51%) is the third-largest convenience store chain and fifth-largest pizza maker (by kitchen count) in the United States, but its stock performance over the last several months has been disappointing.

Down 30% from its all-time high set in June, Casey's is in the midst of its largest pullback since the Great Recession.

CASY Price data by YCharts.

However, while Wall Street frets over short-term valuation concerns, Casey's long-term investment thesis remains intact -- and I'll be looking to add to my position on the dip.

The causes for Casey's 30% sell-off
It has been a rough few months for Casey's for a variety of reasons.

An underwhelming earnings "beat": While Casey's sailed past Wall Street's estimates with sales and earnings per share rising 24% and 28% in its fiscal 2027 first quarter (which ended July 31), a lot of that outperformance was the result of soaring gas prices and higher fuel margins. Expanding its fuel margins from $0.41 per gallon to $0.478 per gallon over the last year served its bottom line well, but it doesn't reflect the actual strength of Casey's earnings, and the feat will be hard to repeat.
Slowing inside sales growth: Rising fuel margins protected the company's earnings, but they may also have eroded its inside sales growth, which slowed to 3.2% from 4.5% last year. Furthermore, while Casey's has a growing assortment of private-label offerings, guests' ongoing shift from national brands to discounted private-label products (for example, sales of name-brand chips dropped 8% as sales of Casey's brand chips grew 16%) suggests consumers are financially stressed.
Full-year guidance unchanged: Management reiterated guidance for earnings before interest, taxes, depreciation, and amortization (EBITDA) growth of 8% to 10% in fiscal 2027, which seemed to disappoint the market. It grew EBITDA by 17% in fiscal Q1, so this would indicate a pretty sharp deceleration, though management stated it may adjust guidance when it delivers its fiscal Q2 numbers.

On top of these issues, perhaps the biggest weight on Casey's stock was its ballooning valuation.

CASY P/E and EV/EBITDA Ratio data by YCharts.

Simply put, Casey's valuation had gotten way out over its skis this summer, but now, it's trading at a much more reasonable level. Valuation isn't everything in Foolish investing, but paying nearly 50 times earnings for a steady Eddie growth stock like Casey's is a bit of a stretch, as much as I love the stock.

The bull case for Casey's remains intact
CASY Casey's General Stores$683.83+$10.20 (+1.51%)

NASDAQ · As of 10:10 AM ET 10/16/26

Now trading at 31 times earnings, Casey's looks reasonably valued again relative to its growth potential, as it plans to add at least 120 new stores this fiscal year to its existing count of 2,959. Management has proven quite adept at making smart acquisitions, a strategy that has helped the company grow from 1,978 stores in 2017. Management plans to add more than 400 stores through 2029, in line with its long-term algorithm of growing its store count by 4% annually.

Image source: Getty Images.

With roughly two-thirds of U.S. convenience stores owned by small-time operators that run one to 10 locations, Casey will have plenty of opportunities to exercise its serial acquisitiveness. This is especially true considering its success in achieving dramatic improvements in sales of prepared food and dispensed beverages at its newly acquired locations. For instance, after acquiring CEFCO Convenience Stores in November 2024, food-and-beverage sales at those locations have risen 30%. By acquiring locations with lackluster or non-existent food-and-beverage operations, Casey's generates an outsize return on investment from its M&A activity after adding its know-how and branding.

This steady expansion -- paired with Casey's 25 straight years of inside same-store sales growth -- makes the company an elite compounder.  Its locations serve as the cornerstone stores in many of the small towns it operates in throughout the Midwest, so Casey's should not only prove hard to disrupt, but also capable of replicating its playbook across the country as it spreads into underserved markets within reach of its current distribution centers.

That said, while I'm bullish on Casey's General Stores over the next decade and beyond, I don't think investors necessarily need to rush in and make a huge bet on the stock today. Operationally, Casey's is great -- but its stock looks like a falling knife right now. While I will feel comfortable adding to my position in two or three tranches between now and the end of 2026, I wouldn't fault investors at all if they'd rather wait to buy until they see sustained signs that the stock's upward momentum has returned, perhaps in tandem with inside sales growth reaccelerating.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Hims between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (""Hims" or the "Company") (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 29, 2026, during market hours, the Federal Trade Commission announced it had filed a lawsuit against Hims "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." On this news, Hims's stock price fell $4.32, or 14.73%, to close at $25.00 per share on July 29, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Hims class action, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Hims Securities Class Action Lawsuit:

What is the Hims securities fraud lawsuit about?

Faruqi & Faruqi, LLP has filed a securities class action lawsuit alleging that Hims & Hers Health, Inc. (NYSE: HIMS) made materially false and misleading statements to investors during the Class Period. The complaint alleges that the Company shared consumers' sensitive health information with third-party advertising platforms despite representing that its services maintain consumer privacy, and that the Company allegedly charged consumers for prescriptions almost immediately after intake form submission while telling consumers they would first be able to consult with a medical provider. The lawsuit further alleges that this conduct subjected Hims to regulatory scrutiny and made the Company reasonably likely to incur fees and penalties. On July 29, 2026, the Federal Trade Commission announced it had filed a lawsuit against Hims alleging these practices, and on that news Hims's stock price allegedly fell $4.32, or approximately 14.73%, to close at $25.00 per share on unusually heavy trading volume. As a result of the foregoing, the complaint alleges that Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NYSE: HIMS) on the NYSE exchange between August 4, 2025 and July 29, 2026, inclusive, may be eligible to participate in this class action lawsuit. Eligibility to participate in any potential recovery is not limited to investors who seek appointment as lead plaintiff; any investor who purchased Hims securities during the Class Period may be a class member. Eligible investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Investors with questions about their eligibility may wish to consult with counsel to better understand their rights and options in connection with this litigation.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who serves on behalf of all class members and plays an active role in directing the litigation, including working with counsel on case strategy and settlement decisions. Any investor who purchased Hims securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff, provided that motion is filed no later than November 2, 2026. Courts typically appoint the investor or group of investors with the largest financial interest in the litigation who also satisfy the requirements of Federal Rule of Civil Procedure 23 as lead plaintiff. Importantly, an investor need not seek appointment as lead plaintiff in order to participate in or share in any recovery that may result from the litigation. Investors who do not seek lead plaintiff status retain the right to remain members of the class and benefit from any judgment or settlement.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Hims securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319254

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Hims & Hers Health, Inc. (HIMS - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this company have returned +5.3%, compared to the Zacks S&P 500 composite's +1.4% change. During this period, the Zacks Medical Info Systems industry, which Hims & Hers Health falls in, has gained 9.1%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Hims & Hers Health is expected to post earnings of $0.07 per share, indicating a change of +16.7% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

For the current fiscal year, the consensus earnings estimate of -$0.79 points to a change of -249.1% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $0.44 indicates a change of +154.7% from what Hims & Hers Health is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Hims & Hers Health is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Hims & Hers Health, the consensus sales estimate for the current quarter of $893.37 million indicates a year-over-year change of +49.2%. For the current and next fiscal years, $3.22 billion and $3.89 billion estimates indicate +37% and +20.8% changes, respectively.

Last Reported Results and Surprise HistoryHims & Hers Health reported revenues of $753.21 million in the last reported quarter, representing a year-over-year change of +38.2%. EPS of -$0.1 for the same period compares with $0.17 a year ago.

Compared to the Zacks Consensus Estimate of $690.21 million, the reported revenues represent a surprise of +9.13%. The EPS surprise was -42.86%.

Over the last four quarters, the company surpassed EPS estimates just once. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Hims & Hers Health is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Hims & Hers Health. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Prefer us on Google

Summary:

USD/JPY rate is stuck between 157.40 and 159.00, caught between high US bond yields and worries about Japanese currency intervention. This long period of consolidation suggests a cautious global risk outlook. Markets aren't strongly risk-on or risk-off, but waiting for clearer policy direction. For a sustained move to happen, new economic catalysts are needed. If the pair closes above 159.00, it would aim for 160.00. The USD/JPY currency pair spent much of October locked in a tight range, generally holding within 157.40 and 159.00.

This sideways action contrasts sharply with the year’s earlier, more volatile trends. It prompts questions about the factors currently stabilizing the pair and whether a decisive break is likely in the coming week.

What’s Keeping the Pair Contained? A few opposing forces are pulling at the pair. The substantial interest rate gap between the U.S. and Japan keeps propping up the dollar. Even with some recent shifts in policy outlooks, this rate difference remains wide enough to fuel carry trades, stopping the yen from gaining much ground.

At the same time, Japanese officials have shown they’re sensitive to the pair nearing 160. Warnings from financial leaders and the market’s memory of past interventions have reliably kept upward moves in check, especially around the top of the current range.

Japan’s Finance Minister said Tokyo and Washington are on the same page and ready to act quickly. This warning isn’t taken lightly. A prior coordinated U.S.-Japan intervention caused the yen to jump, reaching 155 after being above 163. About half of those gains later faded. Now, market players see 160 as a significant level. Sell orders are clustered around 158.20 and 158.35.

Support for the range’s bottom comes down to central bank policy timing. The interest rate difference between the Federal Reserve and the Bank of Japan (BoJ) remains quite large.

With U.S. 10-year Treasury yields staying high after stronger-than-expected inflation numbers, holding U.S. dollars offers a clear yield advantage through carry trades compared to the yen’s low yields. This yield difference helps cushion against sharp drops and maintains a solid floor around 157.40.

U.S. inflation data is high, yet that hasn’t changed market expectations much for an immediate Fed rate hike. Chances of an October increase are about 40% or less.

The BoJ, however, isn’t reportedly planning a rate change in October, even though markets see an 88-90% chance of a December hike. This situation holds back the dollar’s climb and gives the yen little reason to strengthen much right now.

Could We See A Breakout Next Week? A breakout of the 157.40-159.00 channel next week is possible, but it’d probably need a major fundamental event.

Upcoming U.S. producer prices and speeches, including one from Fed Chair Kevin Warsh, might cause some short-term price swings. These usually reverse quickly, though. There aren’t any big economic events scheduled for next week that look like they’ll really move the market.

Without any big triggers, the market will probably just keep moving within its current range. Traders are focusing on range-bound strategies ahead of the central bank meetings later in October.

What’s keeping USD/JPY below 159.00?

Japan’s warnings and a previous joint intervention with Washington make traders wary of pushing the pair toward 160.

What does the sideways pattern tell us about global risk sentiment?

This sideways movement suggests a cautious, wait-and-see attitude. Investors aren’t finding strong reasons to lean into either risk-taking or risk-aversion, holding out for clearer signals from major central banks.

When is a breakout more likely?

A breakout will likely happen around the Fed’s October 27-28 and BoJ’s October 29-30 meetings. Next week seems pretty calm, with few major catalysts on the schedule.

It's no secret that stocks connected to the AI industry have been some of the market's top performers over the past year, but there are still a few that remain relatively under the radar. Silicon Motion Technology (SIMO -2.32%) is one of them. It produces NAND flash controllers, which are vital for AI infrastructure. That's the gist of what the company does, but these three key reasons for buying the stock demonstrate its long-term potential.

Image source: Getty Images.

Silicon Motion Technology works with the leading memory providers Silicon Motion Technology works with the largest memory-chip makers -- Micron (MU +1.87%), Samsung (SSNLF +0.00%), SK Hynix (SKHY -0.98%), and Sandisk (SNDK -0.61%), as well as other fast-growing players. Rising demand for their memory products directly translates into additional revenue for Silicon Motion Technology.

$218.39-$5.19 (-2.32%)

NASDAQ · As of 4:00 PM ET 10/15/26

Some of these customer relationships stretch across more than 20 years, which will make it more difficult for new competitors to gain market share. Silicon Motion Technology has a secure position as a key provider of NAND flash controllers, and it's also working with hyperscalers.

High growth comes at a low valuation Silicon Motion Technology's fundamentals look promising. Its 19.6 forward price-to-earnings (P/E) ratio pairs nicely with revenue that more than doubled year over year in the second quarter. That growth also came with sharply rising margins. Net income jumped from $16.3 million to $136.1 million in Q2.

The company has been enjoying high sequential growth rates for its revenue and profits -- the same condition that has led to steep stock rallies for Micron and Sandisk. Silicon Motion isn't growing as quickly as those two chipmakers, but it's still growing at an accelerated rate compared to many other tech companies. Furthermore, the 20% drop the stock took over the past week was more due to macroeconomic issues than to the company's fundamentals, a point that highlights the nature of the long-term opportunity for investors.

The company has a history of crushing guidance Investors who can tune out the macroeconomic noise and focus on management's latest guidance may see the potential upside of Silicon Motion Technology. The company guided for up to $541 million in third-quarter revenue, which would be a 20% sequential jump. That's already a good number, but Silicon Motion Technology actually has a good history of beating guidance, especially during the AI era.

In the first quarter, Silicon Motion Technology reported $342.1 million in net sales and anticipated up to $411 million in Q2. Its Q2 figure actually came in at $451 million, and when Silicon Motion Technology reported fourth-quarter 2025 results, it told investors to expect up to $306 million in Q1 2026.

In the current memory supercycle, memory product providers have consistently set and beat ambitious revenue targets. Micron did so in its fiscal 2026 Q4, reporting $54.23 billion in revenue compared to the $50 billion guidance figure it offered three months earlier.

Those results are very recent, and they offer good context for what Silicon Motion Technology may do when it next reports earnings on Oct. 29. If Silicon Motion Technology's largest customers are beating guidance, chances are it will do the same.

, /PRNewswire/ -- Beretta Holding S.A. ("Beretta Holding") announced today the preliminary results of its cash tender offer to purchase up to 2,400,184 of the outstanding shares of common stock, par value $1.00 per share (the "Shares"), of Sturm, Ruger & Company, Inc. (NYSE: RGR) ("Ruger") at a price of $44.80 per share in cash (the "Tender Offer"). The Tender Offer expired at one minute following 11:59 p.m., New York City time, on Thursday, October 15, 2026. 

Based on a preliminary count by the depositary for the Tender Offer, a total of 3,589,647 Shares were validly tendered and not properly withdrawn, excluding 2,652,256 Shares tendered by notice of guaranteed delivery.

Because the Tender Offer was oversubscribed, the number of Shares that Beretta Holding will purchase from each tendering stockholder will be prorated to limit the aggregate purchase to 2,400,184 Shares. Based on the preliminary information provided by the depositary, and including all Shares tendered by notice of guaranteed delivery, Beretta Holding estimates that the proration factor for the Tender Offer will be approximately 38.45%. 

The proration factor is based on the depositary's preliminary count and the assumption that all Shares tendered by notice of guaranteed delivery will be delivered within the required one-trading-day period, and is subject to confirmation by the depositary. The final proration factor will be announced following the expiration of the guaranteed delivery period and completion by the depositary of its confirmation process. Payment for Shares accepted for purchase under the Tender Offer, and the return of all other Shares tendered and not purchased, will occur promptly following determination of the final proration factor.

Pietro Gussalli Beretta, Chairman and CEO of Beretta Holding, stated, "This investment represents a significant milestone for Beretta Holding. It marks our first participation in a publicly listed company and opens a new chapter in our development as a long-term investor in the U.S. capital markets. Our cooperation with Ruger expands our position in the United States, our largest market, while creating new opportunities to expand Ruger's presence internationally."

Saratoga Proxy Consulting LLC is the Information Agent for the Tender Offer, and any questions or requests for assistance with respect to the Tender Offer may be directed to Saratoga Proxy Consulting LLC.

Forward-Looking Statements

This press release may contain certain "forward-looking statements," many of which are beyond our ability to control or predict. Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of Beretta Holding. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to the number of Shares to be purchased in the Tender Offer, the proration factor and other risks and uncertainties discussed in the Tender Offer documents filed by Beretta Holding and the Solicitation/Recommendation Statement filed by Ruger. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

SOURCE Beretta Holding S.A.

Meta Platforms (META) grabbed the artificial intelligence spotlight by unveiling an AI chatbot that quickly became a hit among consumers. Meta's Muse — with its cute, fuzzy mascot named Jolly — jumped quickly up the rankings of the most downloaded apps, carrying Meta stock sharply higher along with it.

But that probably won't propel Meta to the lead of the AI race unless it can also grab a chunk of the megatrend's most important market: corporations and other big organizations.

↑
X

How AI Agents Are Changing Who Gets Hired At A $1 Billion Company

Eric Chen, CEO of Injective Labs, says AI agents are boosting productivity at his $1 billion tech company by enabling smaller teams to do more work — reshaping hiring, reducing the need for junior roles and fueling growth.

0 seconds of 15 minutes, 43 secondsVolume 0%

Press shift question mark to access a list of keyboard shortcuts

AI Cyber Threat Sparks Stock Boom. One Analyst Reveals The Must-Own Plays.

16:23

00:00

15:43

15:43

NOW PLAYING
How AI Agents Are Changing Who Gets Hired At A $1 Billion Company

That's what Meta is clearly gunning for with Meta Enterprise Platform, launched less than three weeks after Muse.

It's a tough market to break into as Meta faces entrenched competitors, including Amazon (AMZN), Alphabet's Google (GOOGL), Microsoft (MSFT), Salesforce (CRM) and Oracle (ORCL). But with top AI labs OpenAI and Anthropic making a big push to capture enterprise spending, Meta does not appear content to wait on the sidelines.

The stakes are high for Meta and its stockholders. "Bottom line, they want to compete with the frontier labs," Mizuho analyst Lloyd Walmsley told Investor's Business Daily. "They want to have a model that competes head-to-head and they want to compete for this business."

And the world of business is where the money is in the AI race. "Enterprises are actually parting with dollars to use AI, and consumers are much slower to make this jump," Morningstar analyst Malik Ahmed Khan told IBD.

Meta Stock: Killer Use Cases
Meta Chief Executive Mark Zuckerberg's new enterprise plan could help the company generate returns from the hundreds of billions of dollars it is spending to develop AI models. The company touted its most recent model — Muse Wonder, introduced Monday — as its most powerful yet.

"Traditionally, Meta hasn't been an enterprise company, but we believe that a huge part of the challenge is building the leading models in the first place," Zuckerberg said in an Oct. 12 episode of the "Cheeky Pint" podcast.

He believes "a lot of enterprises" will want to use Muse Wonder.

Meta CEO Mark Zuckerberg speaks at Meta Connect in September. (AP)
Getting enterprises hooked into Meta's AI models could diversify a company that derives nearly all its revenue from social media advertising.

Beyond diversification, the Meta pivot underlines the importance of the enterprise market in the AI race.

Menlo Ventures estimates that consumers will directly spend $40 billion on AI-related services this year. That includes subscriptions and fees based on overall usage. Analysts expect that, similar to social media, revenue from consumer-focused AI will come from advertising sales. Referral fees from e-commerce sales could also drive revenue.

Enterprises, however, are far more likely to pay for AI directly. Analysts at Gartner forecast enterprises will spend $461 billion on AI-powered software this year.

"If you think about killer use cases thus far for AI, including coding, they're mostly geared toward enterprises," Morningstar's Khan said.

Discover Top Growth Stocks With IBD Leaderboard

Meta Scores A Hit With Muse
Launched Sept. 8, Muse is built around a chat function with its cuddly avatar, Jolly. Users can rename and even redesign the mascot. From there, Muse can connect with other apps (such as email, Instagram and calendars) and complete automated tasks when given a goal or objective, like "organize my inbox."

The chatbot has been downloaded more than 9 million times in the U.S., according to data from Sensor Tower. It reached that milestone in just a third of the time it took ChatGPT after its late 2022 launch.

The buzz around the app has put Meta stock back in focus on Wall Street, after fears about its AI spending weighed on shares for much of the year. Meta rallied 27% in September, the stock's best month in more than three years.

Muse's early success marks progress toward Zuckerberg's vision of offering "personal superintelligence" to billions of consumers. But Meta took that a step further on Sept. 28 when Zuckerberg unveiled what he called the "next major pillar" of Meta's business.

Meta's Enterprise Game Plan
"Meta Enterprise Platform will use our strengths that few other companies have: advanced models, leading agents, large-scale infrastructure, and years of working closely with many businesses," Zuckerberg wrote on Threads. "Initially, we will focus on bringing our full technology stack, including the Muse agent, Meta Business Agent, Muse API, Muse Code, and more to businesses and developers to help them grow."

CJ Desai, Meta's first chief enterprise platform officer (Meta)
Zuckerberg is throwing down the gauntlet as the quest begins. To lead the effort, he lured Chirantan "CJ" Desai from his CEO post at MongoDB (MDB). Desai has strong enterprise credentials, with prior roles as president of product and engineering at Cloudflare (NET) and chief operating officer at ServiceNow (NOW).

The same week, Meta announced a Muse for Small Business offering designed to allow entrepreneurs to tap into the AI agent's processing power to accomplish goals.

Meta's AI Overhaul
The enterprise push comes as Meta has muscled its way back into the AI arms race. For much of the past three years, the AI large language models produced by Meta have lagged the performance of the frontier AI labs such as Anthropic, OpenAI and Google.

Zuckerberg last year initiated a drastic overhaul that saw the company spend billions to recruit top researchers.

On Oct. 12, Meta released a new Muse Wonder family of AI models that Zuckerberg said bring Meta "to the frontier." But even before that release, there was evidence that Meta was capitalizing on a new element of the AI race: the harness.

Agents rely on two main layers: the large language model and a so-called harness that essentially hooks that model up to a computer and instructs it on how to complete tasks.

"The model is important and how intelligent it is is important," Willy Lee, a principal at investment firm Neostellar, told IBD. "But how you develop the harness — the instructions and protocols for what the model should do — is almost as important as the model itself."

Muse has caught on with consumers despite not initially offering access to a top AI model. It has just enough AI firepower behind it to handle tasks like canceling underused subscriptions or building a shopping list.

Meta AI Agent Competition
Competition is heating up. Weeks after Meta launched Muse, OpenAI unveiled Dots at its annual developer conference. It has a similar cutesy avatar that is designed to automatically complete tasks based on a user's objectives. While Muse has a free tier that allows users to accomplish most tasks, Dots requires users to have at least the $100-per-month ChatGPT Pro plan.

Meanwhile, Google announced Gemini Agents, which can accomplish tasks across Google Workspace plans and connect with other apps like Slack and Microsoft 365.

Microsoft introduced an updated Copilot AI assistant in late September that combines AI chat, coding tools and autonomous agents into a single product.

Anthropic has not announced a direct competitor to the Muse and Dots personal assistants. However, the AI startup recently merged its agentic CoWork tool into the broader Claude chat interface.

Other competitors for personal AI agents include SpaceX's (SPCX) Grok Bot, which the company describes as "AI teammates" in the workplace. Meanwhile, startup Instinct has gained traction among tech power-users for its ability to act as a personal assistant within text messages, personal calendars and emails.

Meta Stock: 97% Of Revenue From Ads
The early success of Muse offers a chance for Meta to find a second significant source of revenue, something that has proved challenging over its two decades in business.

Analysts project Meta's digital advertising business will drive 97% of its $254 billion in 2026 revenue, according to FactSet. With the dominance of its Facebook, Instagram and WhatsApp offerings, analysts also project Meta will surpass Google as the top digital ad platform by year's end.

But its reliance on a single business, profitable as it may be, makes Meta stand out among its fellow hyperscaler cloud giants. Meta plans up to $145 billion in capital spending this year, focused on constructing data centers. That puts its spending not far behind that of Amazon, Google and Microsoft.

But unlike other hyperscalers, Meta does not rent out its cloud-computing capacity to other enterprises. The chips and servers in its data centers are dedicated to Meta's Family of Apps and its more than 3.5 billion users, as well as its AI efforts.

Amazon, Microsoft and Google have massive businesses renting cloud servers. And from those businesses, they offer a range of hardware and software products. Amazon's cloud business and Google's cloud business are each on track to deliver about one-fifth of their respective company's 2026 revenue, according to analyst projections.

Meanwhile, Meta's most prominent attempt to diversify its revenue — hardware sales from the metaverse — has gained little traction. AI-powered smart glasses and newly introduced subscription fees for Muse and premium Instagram, WhatsApp and Facebook features could help diversify Meta's revenue.

But enterprise may prove the clearest opportunity.

Meta Stock: Sizing Up The Opportunity
Analysts will be looking for further details on Zuckerberg's vision when the company reports earnings on Oct. 21.

Wall Street is bullish on Muse's growth potential overall. In a recent client note, Truist analyst Youssef Squali forecast that Muse could drive $28.5 billion in annual revenue by 2030, with enterprise-related revenue contributing $5.2 billion of that projected spending. That includes revenue from developers building projects through the Muse API.

Squali sees Muse subscriptions driving $10.7 billion in revenue by 2030 and advertising and commerce transaction fees reaching $12.7 billion.

Pivotal Research Group analyst Jeffrey Wlodarczak expects Meta's enterprise business will see a "slow ramp" as it builds up trust, he wrote in a recent note for clients. But he forecasts Meta's enterprise revenue could reach $11 billion by 2030.

Zuckerberg's enterprise announcement also highlighted the Meta Business Agent, which the company made generally available in June.

The agent acts as AI-powered customer support within WhatsApp, Instagram and the Messenger app. Zuckerberg told analysts earlier this year that the company's paid messaging services had crossed a $2 billion annual revenue run rate by the end of 2025, despite only being offered in certain markets.

Meta Stock: Focus For Enterprise
One big question is whether Meta will focus on big corporations or small and midsize businesses, which make up a big chunk of its biggest advertising buyers.

"They already have a deep relationship with millions of SMBs buying Facebook ads and Instagram ads," Mizuho's Walmsley told IBD. "I think that is viewed as a more natural entry to selling cloudlike services or AI compute."

But Zuckerberg recruiting Desai from MongoDB suggests Meta has ambition "far beyond the SMB side," Walmsley noted.

Yet he does not expect Meta to aim to build a business as broad as Amazon Web Services or Google Cloud. Rather, the focus will likely be on offering intelligence-driven services similar to those of Anthropic and OpenAI.

"Selling access to their models, the API business, Muse Code — that is the sort of thing that could scale very quickly without having all the traditional trappings of an enterprise tech company," Walmsley said.

Meta's Previous Enterprise Attempts
Meta tried to enter the enterprise market before. In 2016, the company launched Workplace, a Facebook-like messaging and file-sharing platform focused on businesses. But Meta shut that business down with little fanfare in 2024.

Forrester analyst Naveen Chhabra said it takes time to build credibility among enterprise buyers. Amazon Web Services was founded 24 years ago. Google Cloud is 18 years old.

"A social media platform can have a much faster adoption curve," Chhabra told IBD. "As a consumer, I don't have much investment in adopting a platform. When it comes to enterprise adoption, it has to go through several facets internally."

Google had to steadily build up its range of services to address what enterprise buyers need.

"It takes a lot of preparation to be ready to sell to those audiences," Chhabra added. "Not to say it can't be done, but it cannot be an overnight success."

Trust is also key. This could be a challenge for Meta given scandals over its data practices, including the 2016 Cambridge Analytica scandal.

Performance Of Software Stocks
Still, Meta's enterprise push rattled the enterprise software world.

Software stocks, led by MongoDB, took a hit after Zuckerberg announced his enterprise vision in late September. The reaction brought flashbacks to the fears about AI's impact on software that dominated earlier this year.

But Neostellar's Lee said the broader conversation has shifted from fears that "large language models are going to eat the entire world" to a focus on the "haves and have-nots" of the software sector.

Companies with years of enterprise data and deep integrations into operating systems have a "right to win" in providing the new harness layer for AI systems, he added.

After opening the year on a 30% slide, the software-dominated iShares Expanded Tech-Software Sector ETF (IGV) has bounced back to a 5% year-to-date gain.

IBD's Computer-Software Enterprise stock group now ranks sixth out of 142 industries, based on six-month price performance. The massive 115-stock group includes a number of stocks with Relative Strength Ratings above 95, putting them in the top 5% of stocks based on performance in the last 12 months. They include Twilio (TWLO), Snowflake (SNOW) and Cloudflare.

Meta Stock: Earnings Preview
Meta will release its third-quarter results on Wednesday. Analysts polled by FactSet project that Meta's earnings will come in at $6.67 per share, a huge jump from the $1.05 per share Meta posted in the September quarter last year. However, earnings would have been $7.25 per share in Q3 2025 without a large one-time tax charge.

While Meta is historically a strong earnings performer, its big AI spending has weighed on its finances. Earnings declined 13% for Meta in Q2. The tech giant has an EPS Rating of 83 out of 99. IBD's EPS Rating takes into account the growth and stability of a company's earnings over three years, with extra weighting for the most recent two quarters.

Analysts project Meta's revenue will grow 23.6% to $63.3 billion, according to FactSet. That would mark a deceleration from the 28% growth Meta attained in Q2 and 33% in Q1.

Meta Stock Technical Analysis
While the quick adoption of Meta's Muse AI assistant app powered a huge stock-price gain last month, Meta then pulled back 4% over the first two weeks of October. However, shares rallied following the rollout of Muse Wonder on Oct. 12. They currently trade near 736.

After falling 3% Wednesday, Meta stock appears to be finding support at its 21-day moving average in Thursday's trades. Shares have a Relative Strength Rating of 80, up from 60 four weeks ago.

Further, Meta stock is in a massive 60-week consolidation pattern, as identified by IBD MarketSurge. Meta shares are chasing a record high of 796.23 reached in August 2025, which also serves as a buy point from the consolidation base.

YOU MAY ALSO LIKE:

AI Smart Glasses Will Be Huge. But Meta Faces A Problem.

Check Out Top Growth Stocks To Buy And Watch

Learn How To Time The Market With IBD's ETF Market Strategy

Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Google's quantum lab just cleared a barrier that has quietly set the ceiling on how powerful a quantum computer can ever get, and the implications reach well beyond a single research paper.

Google Quantum AI published “Magic state cultivation on a superconducting quantum processor” in the journal Science on October 15, 2026. The paper is the first hardware demonstration of a technique that cut errors 40-fold compared with states prepared without it.

Class A shares of Alphabet (NASDAQ:GOOG | GOOG Price Prediction, NASDAQ:GOOGL) rose 0.45% that day to close at $349.22, which valued the company at $4.27 trillion. The small move reflects how a stock this large trades on search, cloud, and AI, and investors treated the paper as good science with a distant return.

A lab result like this changes very little. It strengthens a long-term research effort that Alphabet can fund with its own profits.

What Google Demonstrated on Willow The experiment ran on Google’s Willow processor. It produced T-states, a type of magic state, at 99.99% logical fidelity, which means an error rate of 0.0001 or less.

Google researchers Craig Gidney, Noah Shutty, and Cody Jones developed the method in 2024. It places an imperfect state in a small chip region. It checks the state with measurements, discards failures, and extends the survivors into a larger error-correcting code.

Only 8% of attempts passed the filter. Throwing away most attempts is how the method works, because it gives up volume to get quality.

Alphabet CEO Sundar Pichai reacted on X that day. He wrote: “Some magical progress towards “magic state” in quantum!”

Why Magic States Set the Size of a Quantum Computer Complex quantum calculations need magic states. Each one can be used only once, so the machine has to keep making new ones. Some estimates say up to 95% of a quantum computer’s capacity could go to producing them.

Without a cheap, reliable supply of magic states, a quantum computer can only run calculations an ordinary computer already handles, and making them more cheaply reduces how large a machine you would need to build.

How Much Quantum Is Worth to Alphabet Shareholders Alphabet does not report quantum as its own division. The closest line is Other Bets, which brought in $382 million in the second quarter of fiscal 2026. Total revenue that quarter was $119.8 billion.

Google Cloud brought in $24.77 billion in the same quarter, up 82%, and Cloud is what moves the stock. Google disclosed no revenue, customers, or timeline tied to the quantum result.

The quantum lab is paid for by a business that earned $40.77 billion in operating income in that one quarter. Smaller quantum companies depend on investors staying interested enough to fund them.

There’s still a bottleneck.

Magic states are still a constraint. Cultivation now has to work at a much larger scale, inside a machine running a useful calculation, before it changes what quantum hardware can do.

Other large technology companies and smaller listed quantum firms have their own error-correction plans; Google leads in one technique, and the field is competitive.

What Drives Alphabet’s Valuation From Here Alphabet’s investment case rests on the core business, and quantum is a long-term research effort that shareholders get at no added cost.

The shares are up 11.79% so far in 2026 and 39.48% over the past year. They trade at about 16 times trailing earnings. But that multiple looks cheaper than it really is because second-quarter net income included a $99.03 billion gain on equity securities.

The main risk is spending. Second-quarter capital spending, the money spent on data centers and equipment, reached $44.92 billion, and free cash flow, the cash left after that spending, was negative $5.86 billion. That expansion also feeds a long list of suppliers in power, cooling, and networking (we featured seven of them in a free report on the AI infrastructure trade).

The thing to check is Cloud growth in the third-quarter earnings report. If growth stays near the second quarter’s pace, the case for the stock holds. A sharp slowdown would hurt the stock far more than a quantum paper could help it. On the quantum side, look for a follow-up paper showing cultivation supplying a logical computation at larger scale.

Contact [email protected] for any questions or corrections.

AMD cleared $600 twice and failed twice, and that pattern is telling investors something the revenue growth numbers alone cannot explain. Two quarters of upcoming shipment data will determine whether the 2027 bull case survives or collapses.

Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) trades at $562.23. The stock’s failure to stay above $600 shows the market has stopped paying for AI potential and is waiting for proof.

AMD sells server CPUs, AI accelerators, PC chips and embedded processors. Data Center now accounts for 58% of revenue. Shares are up 162.53% year to date and reached a 52-week high of $658.52. In the past week they fell 9.42% from $620.68 as a global tech rout on AI funding worries spread across chip stocks.

Gigawatt Contracts Support the Bull Case After the Pullback
Second-quarter revenue rose 50.1% to $11.54 billion. Data Center sales jumped 107% to $6.72 billion. Guidance calls for about $13 billion in third-quarter revenue. AMD also has anchor deals for up to 2 gigawatts with Anthropic, 6 gigawatts with OpenAI and up to 6 gigawatts with Meta Platforms (NASDAQ:META). Management sized its revenue per gigawatt at “double digit billions”.

On a forward basis the valuation looks reasonable. The stock trades at a forward P/E of 40 with a PEG of 0.626. The 2027 EPS consensus has rose to $15.7219 from $13.2815 90 days ago, which puts the stock at roughly 36x next year’s earnings. CEO Lisa Su expects to “significantly exceed our $20 annual EPS target”.

A 154x Trailing Multiple Has No Cushion for AI Funding Doubts
AMD trades at 154 times trailing earnings and 22.56 times sales. Free cash flow fell 9.9% last quarter, while capital spending rose 186.52%. Gaming revenue dropped 31%. Management also expects data-center AI gross margins to run slightly below the corporate average.

The bigger threat is concentration. Most of the 2027 story rests on a small group of AI labs and hyperscalers. Headlines about cracks emerging in the AI trade go straight at that funding (we profiled seven suppliers supporting the AI expansion, from power to cooling, in a free report you can grab here). With a beta of 2.454, AMD is likely to fall harder than the market when mood sours.

Helios Shipments Will Settle What $600 Could Not
Revenue is growing and margins are expanding, which supports the case for upside. The valuation and the funding questions around AMD’s customers moderate it. The third-quarter guide implies growth of 41%, down from 50.1%. That gives bears a slowing story until Helios volumes show up in the numbers. Su said “Q4 is a step up and then Q1 will be a further step up.”

Analysts See Upside, but Momentum Has Stalled
The average price target of $636.21 implies about 13.2% upside from $562.23. Targets are estimates rather than guarantees. All 55 analysts covering the stock split as follows:

Strong Buy: 5
Buy: 39
Hold: 11
Sell: 0

Over one year AMD gained 135.64%, while the S&P 500 rose 16.03%. Last week AMD lost 9.42% as the index slipped just 0.28%. The stock still trades above its 50-day average of $534.75.

Helios Revenue Is the Catalyst AMD Investors Need to Track Now
At $562.23, AMD sits between its bull and bear cases.

The move around $600 shows buyers will pay for AMD’s AI growth, but only up to a point while the funding behind it is in question. The third-quarter report needs to beat the $13 billion guide and confirm that Helios shipments have started. Gross margin also needs to hold near 56%.

A fourth-quarter guide that shows the promised Helios step-up would support the bullish argument. Any delay from an anchor customer tied to financing would strengthen the bear case. Further drops remain possible in a volatile market, and the stock remains 14.6% below its high.

The next two quarters of Helios revenue will show whether the 2027 estimates are realistic, and they are the key data point for investors to keep an eye on.

Got $1,000? Before You Buy AMD, Read ThisIf you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And AMD wasn't one of them.

They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>

Contact [email protected] for any questions or corrections.

Jensen Huang admits Nvidia can only fill about 70% of current demand, and Taiwan's government just backed a multibillion-dollar bet that moving suppliers to Texas soil changes that equation for both Nvidia and TSMC.

Supply is the tightest constraint on Nvidia (NASDAQ:NVDA | NVDA Price Prediction). On its August 26, 2026 earnings call, CEO Jensen Huang said, “our entire supply chain is challenged,” and Taiwan now wants to move part of that chain to Texas.

In remarks reported October 16, 2026, Taiwan’s economics minister, Kung Ming-hsin, spoke. He said the government supports a plan for U.S. industrial parks, starting in Texas, with the first complex costing up to $4 billion. The parks target smaller suppliers that serve Taiwan Semiconductor Manufacturing (NYSE:TSM) and AI server assemblers such as Foxconn, placing them near Nvidia and other data center hardware makers.

The two names dropped on October 15, 2026, during a wider tech selloff over AI funding worries. Nvidia closed at $217.23, down 1.84%, and TSMC’s U.S. shares closed at $422.25, down 1.80%.

If you own either stock, the question is whether a supplier park matters to companies this large. It matters more to TSMC’s U.S. ecosystem than to Nvidia’s earnings.

What Taiwan Has Committed The plan is a statement of intent, backed by government support. The Taiwan Electrical and Electronic Manufacturers’ Association, an industry group, is expected to raise the money, and the government will offer loan guarantees, visas, and land access.

Kung Ming-hsin put each site’s estimated cost at $2 billion to $4 billion, and the government wants more than one U.S. location but has not set a number. Nvidia, TSMC and Foxconn have made no commitment to the parks, and no participating suppliers, schedule or customer contracts were named.

What Nvidia Gains From Local Suppliers AI servers rely on smaller makers of power supplies, cooling systems, circuit boards, connectors and chassis. Placing them near U.S. assembly cuts shipping time and tariff exposure, which also helps Nvidia’s standing in Washington (we profiled seven of these non-chip AI infrastructure suppliers, from power to cooling, in a free report you can grab here).

One site is small, with $96.22 billion in quarterly revenue and $279 billion in supply commitments. U.S. production usually costs more, although forecast gross margin of about 74% suggests Nvidia has room to pass those costs to customers.

Taiwan also addressed AI hardware policy. Shipping restricted AI hardware to mainland China will become “a criminal offense under the Foreign Trade Act.” That lowers the risk of leakage, and Nvidia’s guidance already excludes Data Center compute revenue from China.

Why TSMC Sits Closer to the Buildout TSMC’s planned U.S. investment reached $265 billion after it added $100 billion for Arizona in July. A Texas supplier park is small beside that, but it puts parts makers between the Arizona fabs and the server assemblers.

TSMC is also studying Texas. Describing capacity options outside Arizona on its October 15, 2026 call, management said, “And Texas is one,” and added that teams are evaluating options, with no investment announced.

Permitting, U.S. labor costs, and whether enough suppliers sign up are all unresolved. Larger Taiwanese firms are already moving on their own. Quanta Computer won approval to spend $973 million on server assembly in Tennessee, and Wistron won approval for $146 million to upgrade a Texas plant.

Taiwan’s semiconductor exports hit a record $87.22 billion in September, up 60.9% from a year earlier, so the demand exists now. The parks assume it holds up long enough to cover higher U.S. costs.

How Texas Supplier Parks Could Shape the Outlook for Nvidia and TSMC Supply remains the main limit on Nvidia’s growth. Huang said the company has supply for about 70% of demand, so added U.S. capacity helps marginally.

TSMC has more direct exposure to the reshoring theme, because it runs the fabs a Texas cluster would serve. Its $1.95 trillion market value, against Nvidia’s $5.25 trillion, also gives local suppliers more weight in its story.

The signal to check is an announcement naming the first suppliers in a Texas park, along with a confirmed site and schedule. Until then, Kung Ming-hsin’s $4 billion figure is only an upper estimate for one site.

Contact [email protected] for any questions or corrections.

News Summary:

NVIDIA RTX Spark laptops are available today from ASUS, Dell, HP, Lenovo, Microsoft and MSI — with additional systems to follow — bringing RTX acceleration and NVIDIA’s full-stack AI platform to slim, premium Windows PCs for creation, gaming and local AI.RTX Spark delivers up to 1 petaflop of AI compute and up to 128GB of unified memory — enabling AI developers, creators and gamers to run frontier AI models locally, render 90GB+ 3D scenes and play AAA games at 1440p at over 100 frames per second, all on a slim, portable device.Day-one support across local AI agents, creative apps and major games helps users put RTX Spark to work immediately — from editing with Adobe Photoshop and Premiere to running Hermes and OpenClaw agents and playing titles including Gears of War: E-Day and NBA 2K27 with NVIDIA DLSS 5.
SANTA CLARA, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NVIDIA today announced the availability of NVIDIA RTX Spark™ laptops, bringing together RTX graphics and NVIDIA’s full-stack AI platform in slim, premium Windows PCs for accelerated creation, immersive gaming and powerful local AI — rolling out from ASUS, Dell, HP, Lenovo, Microsoft and MSI.

Combining decades of NVIDIA innovation into a single superchip, RTX Spark delivers up to 128GB of unified memory and 1 petaflop of FP4 AI performance to run large language models and AI agents locally. On a single device, creators, developers and gamers can move seamlessly between their everyday workflows and emerging AI agents on the familiar Windows platform.

“RTX Spark brings the power of NVIDIA AI, RTX graphics and CUDA together with Microsoft Windows in one PC for creating, gaming and running personal AI agents,” said Jensen Huang, founder and CEO of NVIDIA. “Together with Microsoft and our PC industry partners, we’re bringing creators, developers and gamers a new generation of Windows PC, built for the work they do today and the personal AI agents they’ll work with next.”

“We’re building Windows to be the platform for hybrid intelligence, where AI can run locally when it makes sense and reach the cloud when needed,” said Yusuf Mehdi, executive vice president at Microsoft. “Windows PCs powered by RTX Spark unlock powerful new local compute for creators and developers, expanding what they can create, build and run on Windows.”

A New Beginning for Windows PCs
RTX Spark brings NVIDIA’s accelerated computing platform to a new generation of portable Windows PCs.

At its foundation is a single superchip combining an NVIDIA Blackwell RTX GPU and an NVIDIA Grace CPU with up to 128GB of unified memory and up to 1 petaflop of FP4 AI performance. That shared memory allows demanding creative projects and local AI models to run simultaneously and efficiently. MediaTek collaborated with NVIDIA on the custom CPU design, contributing to its best-in-class power efficiency, performance and connectivity.

All of NVIDIA’s platform innovation comes together in RTX Spark — NVIDIA CUDA®, DLSS, OptiX™, Reflex, G-SYNC®, TensorRT™ and hardware-accelerated video — in a device that fits in a messenger bag. Slim, efficient designs and all-day battery life bring these capabilities wherever users create, develop and play.

From Tool to Teammate
RTX Spark gives users the capabilities to deploy local AI agents that turn the PC from a tool into an everyday teammate that can complete tasks, generate assets and write code.

Users can put agents to work immediately. Guided setup and easy installers help users get started with agents, including GitHub Copilot, Hermes, OpenClaw, Perplexity, Pi and WorkBuddy, without requiring a command line.

“Personal AI becomes more useful when it can work with your tools and help get things done,” said Dillon Rolnick, CEO at Nous Research, creators of Hermes Agent. “We brought Hermes to RTX Spark so people can put open AI models and agents to work locally on a Windows laptop, with greater control over their data and the freedom to shape AI around their own workflows.”

NVIDIA’s models and tools build on that ecosystem. Nemotron 3.5 Bolt 74B-A9B 24GB, a 74-billion-parameter model optimized for tool calling and multistep tasks, brings more capable local AI to supported RTX Spark configurations.

The NVIDIA OpenShell™ secure runtime and Microsoft Execution Containers help users control agent permissions, while NVIDIA agent skills let compatible agents work with tools including NVIDIA Broadcast, RTX Remix and Omniverse™ libraries. For example, compatible agents can adjust Broadcast effects during a stream or batch-process recorded clips, all on a local PC.

That experience extends across devices with NVIDIA PAIR, letting RTX Spark serve AI inference to compatible Windows, Linux and macOS computers on a home network while keeping other PCs free for creating and gaming.

Create, Innovate, Play
RTX Spark helps creators move from an idea to finished content wherever they work, with the ability to edit 8K 4:2:2 video and render large 3D scenes up to 90GB, even when unplugged.

With the arrival of RTX Spark, Adobe is enhancing its industry-leading creative applications, including Photoshop, Premiere and Substance 3D, with NVIDIA TensorRT acceleration in AI-editing features. In Premiere, creators can work faster across some of the most intensive parts of post-production, from playback and rendering to effects, color grading and more. Photoshop and Premiere offer native RTX Spark support through beta releases available at launch, with Substance coming soon.

“Creatives are pushing the boundaries of what’s possible across image, video, audio and 3D, and they need tools that can keep up with their ambitions,” said Deepa Subramaniam, vice president of product marketing for creative professionals at Adobe. “By combining NVIDIA’s advanced computing technology with Adobe’s industry-leading creative applications, we’re delivering enhanced experiences that empower creatives to bring their ideas to life with greater power and speed.”

For enhancing recorded content, NVIDIA Broadcast 2.3 lets creators remove background noise from existing recordings and shape their voice with Studio Voice Mic Profiles. Beta RTX Video features enable up to 4K super resolution and 4x frame generation.

In ComfyUI, new RTX Video nodes can turn 15 frames-per-second (fps) AI-generated video into smoother 60 fps footage and convert it to high dynamic range without requiring per-use cloud inference charges.

Code, Test and Deploy With One Machine
As AI shifts software development from writing code to directing agents, work often spans a laptop, a cloud AI model and a cloud virtual machine for testing.

RTX Spark brings coding, testing and prototyping onto one machine. Native CUDA support lets developers run models and agents locally, keeping locally processed code and context on their device with a path to deploy across more than 150 million NVIDIA RTX™ AI PCs and NVIDIA GPUs in the cloud. Windows Developer Config streamlines setup, while Windows Subsystem for Linux provides familiar Linux tools used in cloud development.

NVIDIA Skills, an open source GitHub repository, teaches agents to use NVIDIA CUDA-X™ tools and libraries, helping developers build NVIDIA-accelerated apps without CUDA expertise.

NVIDIA and Microsoft have readied developer tools for RTX Spark, including the first PyTorch-CUDA build for Windows on Arm, the first Python build that is native by default, the first native Conda installer, support for 97% of the top 15,000 Python packages, and coding agents such as GitHub Copilot and Pi.

Game Ready With Hundreds of Games
RTX Spark brings immersive gaming to the same portable Windows PC used for creating and developing, with NVIDIA Blackwell RTX graphics enhancing image quality and accelerating performance in supported titles.

Launch support spans single-player adventure and online multiplayer games including Cyberpunk 2077, Fortnite, Gears of War: E-Day, Marvel Rivals, World of Warcraft and NBA 2K27.

NBA 2K27 showcases that immersive experience, using NVIDIA DLSS 5 technology with the 3D-Guided Neural Rendering feature to enhance lighting and material details for greater realism. A new 2x faster AI model, available today, boosts DLSS 5 frame rates by up to 1.4x. NVIDIA’s suite of RTX gaming technologies — DLSS, ray tracing, G-SYNC and Reflex — bring sharper visuals, smoother gameplay and greater responsiveness.

“Bringing the energy of NBA basketball to life means making every detail feel authentic,” said Peter Kavic, senior producer for visual concepts at 2K. “We worked with NVIDIA to bring ‘NBA 2K27’ to RTX Spark, using DLSS 5 with 3D-Guided Neural Rendering to deliver richer lighting and boost the visual quality of materials to deliver a jump in photorealism on a new generation of slim laptops and compact desktops.”

Availability
RTX Spark laptops are available globally today from ASUS, Dell, HP, Lenovo, Microsoft and MSI through their websites and major retailers, starting at $2,599, with a limited-time promotion for new Perplexity users. Pricing and configurations vary by region.

The lineup of RTX Spark laptops includes ASUS ProArt P14 and P16, Dell XPS 16, HP OmniBook Ultra and OmniBook X 14, Lenovo Yoga Pro 9n, Microsoft Surface Laptop Ultra, and MSI Prestige N16 Flip AI+ and Prestige N16.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Stephenie Ngo
Consumer PR
NVIDIA Corporation
[email protected]  

Certain statements in this press release including, but not limited to, statements as to: expectations with respect to growth, performance, availability, and benefits of NVIDIA’s products, services and technologies, and related trends and drivers; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments, and related trends and drivers; projected market growth and trends; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing products and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Copies of reports filed with the SEC are posted on NVIDIA’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, and other NVIDIA product and service names are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries and regions. Other company, product, and service names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/69194cf4-c124-4040-b96b-1db2655172fd

Five Walmart milestones generated five very different outcomes for investors who bought on the headline. Which entry turned $1,000 into nearly $6,000, and which one left buyers underwater despite years of patience?

The Walmart (NASDAQ:WMT | WMT Price Prediction) events with the biggest headlines turned out to be some of the worst days to buy the stock. Below, we follow $1,000 from five points to a common end price of $117.67, quoted in premarket trading on October 16, 2026. Entry prices are adjusted for splits and dividends, so they show what a buy-and-hold investor actually got.

Jet.com Buyers Turned $1,000 Into $5,725.70
Walmart announced the Jet.com deal on August 8, 2016. It was the company’s answer to the dominant online leader in e-commerce, Amazon.com (NASDAQ:AMZN), and many people questioned it at the time. The adjusted entry price was $20.55. Since then, the stock has gained 472.57%, so $1,000 became $5,725.70. That makes it the best entry on this list. Global eCommerce now accounts for 24% of total net sales.

Pandemic Buyers More Than Tripled Their Money
On February 26, 2020, the adjusted price was $34.63. Walmart was named an essential retailer and kept its stores open while much of retail shut down. That entry is up 239.78%, turning $1,000 into $3,397.80.

Dividend King Day Still Returned 150.11%
On February 21, 2023, John David Rainey, Walmart’s CFO, marked fifty consecutive years of annual dividend increases in the company release: “We’re proud to be increasing our annual dividend for the 50th consecutive year, a milestone for our company.” That run puts Walmart in the Dividend Kings club. (We ranked ten of them by valuation in a free report.) From an adjusted $47.05, the stock returned 150.11%, so $1,000 grew to $2,501.10.

Stock Split Buyers Doubled Their Money Anyway
The split took effect on February 26, 2024. This split drew heavy retail attention and a wave of coverage, though the underlying business stayed the same. From an adjusted $57.97, the stock has returned 102.98%, and $1,000 is now worth $2,029.80.

Modern All-Time High Buyers Are Underwater
Walmart hit its modern all-time high on May 19, 2026, at an adjusted $133.88. The stock has since dropped 12.11%, leaving a $1,000 investment at $878.90. Shares have gained 8.86% over the past month after Deutsche Bank called the stock a Buy, but that rally hasn’t erased the loss.

Walmart Beat the Market Over Five and Ten Years
S&P 500 figures are price-only and exclude dividends.

Year to Date: 6.29% vs. S&P 500’s 13.18%
1-Year: $1,000 became $1,088.30 (8.83%); S&P 500 $1,160.30 (16.03%)
5-Year: $2,673.40 (167.34%); S&P 500 $1,731 (73.1%)
10-Year: $6,114.10 (511.41%); S&P 500 $3,634 (263.4%)

Your Entry Price Mattered More Than Your Holding Period
The buyer at the modern all-time high is losing money, while the Jet.com buyer has multiplied their stake more than five times. Milestone headlines report a move that has already happened. What you paid counted far more than how long you held.

Walmart’s upside depends on whether its higher-margin businesses keep compounding. Last quarter, global advertising grew 38%, membership fees rose 17%, and management raised its fiscal 2027 adjusted EPS guidance to a range of $2.80 to $2.87. Downside risks center on a thin margin of safety. A P/E near 43 is a steep price for a retailer with a 3.1% net margin, and tariff refunds lifted last quarter’s results.

The data favor patience. The business is performing well, but these five entry points show that buying with discipline has paid better than buying on headlines.

Contact [email protected] for any questions or corrections.

In recent years, artificial intelligence (AI) stocks soared in the triple and quadruple digits, leading the S&P 500 higher. Investors rushed to get in on the next big tech growth story, a technology with the potential to transform how many things are done and, as a result, fuel significant gains in corporate earnings. Companies such as AI chip designer Nvidia and memory chip providers Micron Technology and Sandisk have seen their shares skyrocket, and the positive momentum continues today.

But this year, AI stocks haven't been the only growth story. In fact, though they continue to advance, investors have expanded into other industries and turned their attention to new growth opportunities. And this brings me to the stock I'll talk about right here.

This particular company, a biotech innovator, has seen its shares surge more than 600% this year, largely outperforming Nvidia, Micron, Sandisk, and many other top-performing AI stocks. And just a few days ago, it entered the prestigious Nasdaq-100, an index that tracks the biggest non-financial Nasdaq companies.

This stock has been a clear winner for investors this year. But after its enormous gain, is it too late to buy now? Let's find out.

Image source: Getty Images.

Moderna's coronavirus blockbusterThe stock I'm talking about has known both tremendous increases and major declines in past years. This company is Moderna (MRNA +4.51%), a biotech that made headlines when it brought its coronavirus vaccine from the drawing board to commercialization in less than a year. That was during the early days of the pandemic, and the vaccine, the company's first commercialized product, became a blockbuster, bringing in more than $18 billion at its peak in 2022. Investors piled into Moderna stock, pushing it to a gain of more than 2,000% over about a year and a half.

MRNA Moderna$236.50+$10.20 (+4.51%)

NASDAQ · As of 4:00 PM ET 10/15/26

In recent years, however, Moderna faced significant headwinds. Demand for the vaccine declined in the later days of the pandemic, the company's respiratory syncytial virus (RSV) vaccine has struggled to gain market share, and Moderna's much-anticipated cytomegalovirus (CMV) vaccine candidate failed in a phase 3 study.

But Moderna has progressively turned things around. The company cut costs to match the current coronavirus vaccine revenue opportunity, won approval of new products such as a flu vaccine and new coronavirus vaccine updates, and focused its pipeline on oncology and rare diseases in addition to respiratory illnesses. In fact, the progress in oncology has been a catalyst for the stock's performance this year.

Moderna is studying intismeran autogene, a personalized cancer vaccine, in 10 clinical studies, with the most advanced in phase 3. In August, the company announced that intismeran autogene in combination with Merck's Keytruda met its goals of recurrence-free survival and survival without the spread of disease to distant organs in patients with melanoma. The companies said they would "engage with regulators on filing submissions," suggesting a new product approval for Moderna may be on the horizon.

Surpassing Wall Street's price targetsModerna had already climbed about 100% this year prior to that news, but the stock soared thereafter, pushing it to gains that surpass those of the AI companies I mentioned earlier. And the stock, trading at around $225, surpasses the average Wall Street 12-month price estimate of $122.

MRNA data by YCharts

Now, let's get back to our question: Is it too late to buy this hot biotech stock? Moderna has a bright future ahead, with new products generating revenue and a late-stage pipeline that should deliver fresh revenue streams moving forward. So Moderna is no longer only a coronavirus vaccine company, and instead is transforming into a larger biotech company with the ability to address a broad range of treatment areas.

Moderna makes a fantastic stock to own, and it should have plenty of room to run in the future as it wins approval for some of its promising pipeline candidates and generates revenue. That said, considering the stock's massive increase this year, I would watch it closely and wait for an opportunity to buy on the dip.

Travelers (TRV - Free Report) came out with quarterly earnings of $9.18 per share, beating the Zacks Consensus Estimate of $7.07 per share. This compares to earnings of $8.14 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +29.84%. A quarter ago, it was expected that this insurer would post earnings of $5.31 per share when it actually produced earnings of $10.04, delivering a surprise of +89.08%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Travelers, which belongs to the Zacks Insurance - Property and Casualty industry, posted revenues of $12.45 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 0.41%. This compares to year-ago revenues of $12.44 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Travelers shares have added about 32.4% since the beginning of the year versus the S&P 500's gain of 13.1%.

What's Next for Travelers?While Travelers has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Travelers was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $9.40 on $12.37 billion in revenues for the coming quarter and $34.25 on $48.82 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Insurance - Property and Casualty is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, HCI Group (HCI - Free Report) , has yet to report results for the quarter ended September 2026.

This property and casualty insurance holding company is expected to post quarterly earnings of $5.01 per share in its upcoming report, which represents a year-over-year change of +2.2%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level.

HCI Group's revenues are expected to be $248.59 million, up 14.9% from the year-ago quarter.

GIBRALTAR, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aurora Intents, the cross-chain execution solution built by Aurora Labs, now powers deposits intoElara Finance directly from Solana. Solana users can now deposit into Elara, a treasury product from the Brila ecosystem, with one signature from their Solana wallet. Staked as sELUSD, Elara's stablecoin elUSD earns yield from stablecoin market making, giving Solana users a way to put idle stablecoins to work without leaving their wallet.

Moving tokens across chains is only half the problem. The harder part is doing something with them once they arrive: minting, staking, depositing. Intents Connect handles that last step, so an app can let users act on another chain from the wallet they already use.

Funds move to Ethereum, where Elara mints elUSD. From there, the user stakes it into sELUSD with a second signature from the same Solana wallet. Both tokens stay on Ethereum in an account controlled by the user’s Solana wallet. Aurora Intents never holds the funds.

"Every extra step between a user and a product costs that product deposits," said Declan Hannon, CEO of Aurora Labs. "Bridging and buying gas are two steps most Solana users would rather skip. Elara can now accept those users as they are, and Aurora Intents handles everything in between."

The return trip works the same way. Users unstake sELUSD, redeem ELUSD for stablecoins, and Aurora Intents returns the funds to their Solana wallet.

“Our job is to make idle stablecoins productive, and a lot of that capital is held on Solana,” said Sebastien Davies, Head of Strategy, Elara. “Aurora Intents gives those holders a direct route into Elara without bridging or managing a second wallet. It brings our yield to them, wherever their funds are.”

Today’s launch connects Solana wallets to Elara, with deposits and withdrawals handled from the same wallet. The Solana route is live now at app.elara.fi.

Aurora Intents powers that connection through NEAR Intents, a solver network that has processed more than $34 billion in transactions.

About Aurora Intents

Aurora Intents is the cross-chain execution layer for on-chain applications. It enables users and systems to move assets, execute actions, and access liquidity across chains - without bridging screens, wallet switching, or per-chain gas management. Aurora Intents is built on top of NEAR Intents, the underlying solver network developed by NEAR Protocol.

About Elara Finance

Elara Finance is a treasury management product from the Brila ecosystem. Users deposit stablecoins to mint elUSD, a dollar-referenced treasury asset, and stake it as sELUSD to earn yield from stablecoin market making.

Media Contact:
Maha Shah
Associate PR Director
[email protected]

Disclaimer:This sponsored content is provided by the content provider and does not necessarily reflect the views of this media platform or its publisher. The information is shared for general informational purposes only and should not be considered financial, investment, or trading advice. Cryptocurrency and mining-related activities carry risks, including the potential loss of capital, and readers are encouraged to conduct their own research and seek professional advice where appropriate. Speculate only with funds that you can afford to lose.The media platform and publisher assume no responsibility for any losses or claims arising from reliance on this content. GlobeNewswire does not endorse any content on this page.

Legal Disclaimer: This article is provided on an “as-is” basis, without warranties or representations of any kind, express or implied. The media platform assumes no responsibility or liability for the accuracy, content, completeness, legality, or reliability of the information presented. Any complaints, claims, or copyright concerns related to this article should be directed to the content provider mentioned above.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c0870d77-522d-481a-83b1-1cf16b7fe146

Aurora

Aurora Source: Aurora

Key Takeaways Medtronic is targeting high-growth markets, with cardiac ablation sales surging 88% worldwide.MDT's hypertension growth gains support from better reimbursement, clinical evidence and hospital adoption.MDT expands MedSurg growth through Hugo robotics and Touch Surgery amid tariff and currency pressures.
Medtronic plc (MDT - Free Report) is expanding its presence in high-growth markets, including cardiac ablation, robotics and structural heart, while advancing the MiniMed separation. Hypertension is a growing focus for the company, aided by improved reimbursement, clinical evidence, hospital adoption and workflow integration. MedSurg growth is supported by robotics, digital surgery and core procedural technologies, with Hugo and Touch Surgery expanding adoption. Meanwhile, Medtronic faces tariff, inflation, product-mix and currency risks that could pressure margins.

Over the past year, this Zacks Rank #3 (Hold) stock has risen 0.1% against the industry’s 26.6% fall and the S&P 500 composite’s 16.6% jump.

The renowned medical device company has a market capitalization of $120.53 billion. Medtronic has an earnings yield of 6.4% compared with the industry’s yield of 2.7%. MDT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.76%.

Let’s delve deeper.

Tailwinds for MDTStrategic Focus to Capture Several Growth Markets: Medtronic is expanding in cardiac ablation, neuromodulation, diabetes technologies, surgical robotics and other faster-growing adjacencies. This approach lets the company concentrate investment in categories where differentiated innovation can support multi-year growth. In the first quarter of fiscal 2027, organic revenues rose 13.7%, including an estimated 670-basis-point (bps) benefit from the extra selling week. Excluding that benefit, management said the quarter delivered its best performance in nearly eight years outside pandemic-related comparisons. CAS remained the clearest growth driver, increasing 88% worldwide as Affera and Sphere-9 adoption expanded.

Medtronic also completed the Scientia Vascular and SPR Therapeutics acquisitions, which are expected to contribute more than $150 million of inorganic fiscal 2027 revenues. Both operate in markets with annual growth rates above 20%, increasing exposure to faster-growing categories. Strategic investments in Cornerstone Robotics and Pi-Cardia expand Medtronic’s exposure to robotics and structural heart, while the MiniMed separation remains on track for completion before fiscal year-end.

Image Source: Zacks Investment Research

Hypertension, A New Focus Area: Medtronic’s Hypertension business is building the Symplicity Spyral renal denervation franchise as reimbursement, clinical evidence and workflow integration improve. Procedure momentum increased following the final Medicare National Coverage Determination. At the end of fiscal 2026, average weekly procedures doubled after the decision, while the franchise annualized at about $100 million. In the first quarter of fiscal 2027, management cited progress in access, market development and adoption, with more hospitals approaching Medtronic about establishing programs.

The SPYRAL AFFIRM clinical trial was accepted as a late-breaker for TCT in fall 2026, extending the evidence base. The company also expects to launch a transradial catheter in the second half of fiscal 2027, which should make the therapy easier to integrate into established interventional workflows.

MedSurg Growth Prospects Remain Favorable: Medical Surgical is benefiting from broader adoption of robotics, digital surgery and core procedural technologies. First-quarter fiscal 2027 revenues increased 10.2% organically compared with 2.9% growth in fiscal 2026. Surgical & Endoscopy rose 9%, supported by Advanced Energy, Wound Management, Endoscopy and a larger Hugo contribution. Management expects Hugo to exceed 50,000 completed procedures by fiscal 2027 year-end, with procedure growth running at more than twice the market rate.

Touch Surgery is now used in more than 1,500 operating rooms globally, while FDA clearance for Touch Surgery Aide expands the digital surgery platform. The Cornerstone Robotics agreement broadens Medtronic’s robotics offering and is expected to contribute to growth and margins beginning in fiscal 2028.

Downsides for MDTMacroeconomic and Margin Risks Persist: Medtronic remains exposed to changing global trade policies, inflation and geopolitical disruption, which can raise operating costs and complicate margin recovery. Tariffs were only a slight drag in first-quarter fiscal 2027 as payments were largely offset by refunds, but the benefit may not persist as trade policies evolve. Product mix also remained unfavorable by 50 bps, mainly due to Diabetes and CAS. Pricing and cost of goods sold (COGS) efficiency provided offsets during the quarter, yet continued investment in commercialization and portfolio expansion could absorb part of those gains.

Exposure to Currency Movement: Medtronic’s large international presence leaves reported results sensitive to exchange rates. Fiscal 2027 guidance now assumes a $50 million to $150 million revenue drag from foreign exchange, while the EPS impact is expected to be neutral to a 1% benefit.

MDT Stock Estimate TrendThe Zacks Consensus Estimate for Medtronic’s fiscal 2027 earnings per share (EPS) has increased 1 cent to $5.98 in the past 30 days.

The consensus estimate for fiscal 2027 revenues is pegged at $38.97 billion, implying a 7.2% rise from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Abbott (ABT - Free Report) and Globus Medical (GMED - Free Report) .

Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7%. Shares of the company have dropped 3.1% compared with the industry’s 26.6% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%. 

PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT shares have plunged 19.1% compared with the industry’s 26.5% decline over the past year.

Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 35.1% compared with the industry’s 7.8% growth over the past year.

SummaryBroadcom Inc. maintains a Strong Buy rating, with robust AI revenue growth and a clear path to its $115B 2027 target.AVGO needs only ~12% quarterly AI revenue growth to hit 2027 goals, a marked slowdown from recent quarters, suggesting achievable targets.Networking, comprising ~27% of AI revenue, is poised to grow as fast as custom chips, supporting margins and diversified exposure.Significant lending to AI customers like Anthropic and OpenAI introduces risk, but AVGO's strong cash flow and balance sheet provide a cushion. Sundry Photography/iStock Editorial via Getty Images

Back in September, I argued that Broadcom Inc.'s (AVGO) AI demand story had survived the slowdown scare. But the stock is still about 28% below its record close of about $480 on June 2, 2026.

5.11K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

 | Source: Royalty Pharma plc

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.

The dividend will be paid on December 10, 2026, to shareholders of record at the close of business on November 13, 2026.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
[email protected]

Decades of real-world medical records highlight the diverse challenges of living with classic congenital adrenal hyperplasia and how needs evolve from childhood through adulthood Patient records showed growth and bone-age monitoring in childhood; puberty and reproductive health concerns through adolescence and young adulthood; and increasingly diverse clinical needs in adulthood, while treatment and self-management demands persisted across life stages The analysis captured impacts beyond traditional medical complications, including daily activities, school, work, caregiving, self-management, and access to care Mapping patient experiences over time may help healthcare professionals anticipate evolving needs and inform education, support strategies, and coordination across care teams , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve throughout a patient's life. The findings will be presented at the Endocrine Nurses Society Annual Symposium 2026, taking place Oct. 16-17 in Phoenix.

The analysis used a novel patient journey mapping approach to combine de-identified electronic medical records from CAHtalog®, a registry of patients with classic congenital adrenal hyperplasia (CAH) in the United States developed by Neurocrine in partnership with the CARES Foundation. CAHtalog was designed to characterize treatment patterns over time, natural history, and impact of CAH. The records used for this analysis spanned decades of care across providers, specialties, and health systems, allowing clinical, treatment, monitoring, and humanistic experiences to be examined within individual patients with CAH.

"Classic congenital adrenal hyperplasia is a complex, lifelong disease, and every person living with CAH experiences the condition differently, with needs that change over time," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "By connecting decades of real-world medical records into longitudinal patient journeys, this analysis reveals how the impact of the condition accumulates across the lifespan and highlights challenges that might otherwise be missed in traditional clinical assessments. These insights may help healthcare professionals anticipate periods when patients could benefit from additional education, support, and coordination from their care team."

Electronic medical records from 10 adults (four males, six females) with classic CAH in the CAHtalog registry were used to construct aggregated and sex-stratified patient journeys.* The data comprised more than 2,800 CAH-relevant events representing more than 300 patient-years of medical history. Patient journeys were developed using large language model-assisted analysis and were reviewed and validated by the study team.

Patient records reflected a range of clinical and day-to-day challenges across life stages. Impacts emerged in infancy and centered on diagnosis, treatment, managing acute illness, and preparing caregivers for emergency steroid use. In childhood, records reflected growth-related concerns with bone-age monitoring becoming increasingly important. During adolescence, puberty brought new androgen-related symptoms and challenges with staying on treatment, while monitoring hormone and steroid levels became a greater focus. In young adulthood, new reproductive, surgical, and transition-of-care needs emerged. In adulthood, patients experienced a wider range of health concerns and greater need for imaging and testing.

Treatment, monitoring, caregiver support, and self-management demands recurred and evolved across life stages. Glucocorticoid dose adjustments and stress dosing, or temporarily increasing steroids during illness, injury, or other periods of physical stress, were documented over time in all 10 patients. Records also reflected ongoing monitoring and care coordination, including specialty referrals, changes in providers, treatment access, and the transition to adult endocrinology. Treatment management evolved from caregiver-led support to increasing self-management. These findings underscore ongoing education and preparedness needs for patients and caregivers.

Routine clinical records captured substantial challenges beyond medical complications, extending to school, work, and daily functioning. These impacts evolved over time from challenges managing treatment and progressing in sports during childhood to disruptions in education, work, and physical activity later in life.

While many treatment and weight-related impacts were shared across sexes, the analysis also identified certain sex-specific aspects of care. Menstrual concerns were documented among females, and testicular imaging and testicular adrenal rest tumor concerns were documented among males.

"Nurses are uniquely positioned to understand the full experience of living with adrenal insufficiency — not only the laboratory values and clinical data, but how the condition affects patients and families as they navigate daily life, transitions in care, and changing needs over time," said Louise Fleming, Ph.D., MSN-Ed, RN, FAAN, presenting author and Professor of Nursing at the University of Virginia School of Nursing. "Recognizing the broader patient journey can help us anticipate when additional education, stress-dosing preparation, self-management support or care coordination may be needed. It also allows us to move beyond responding to individual clinical encounters toward providing more proactive, coordinated and patient-centered care across the lifespan."

*This descriptive analysis was intended to provide qualitative insights into patient experiences rather than quantitative estimates, with some observations based on one or two individuals. The findings are illustrative and should not be interpreted as prevalence estimates or evidence of causality. 

Additional Presentations at the Endocrine Nurses Society Annual Symposium 2026 Include:

Long-term Treatment with Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses and Improves Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst® Pediatric
  Crinecerfont Improves Cardiometabolic Outcomes in the Context of Sustained Glucocorticoid Dose Reduction: 2-Year Results from the CAHtalyst Adult Study About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.

Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with supraphysiologic GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to cardiometabolic and fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).

About the CAHtalog® Registry
In 2021, the CARES Foundation, Neurocrine Biosciences and PicnicHealth partnered to establish the CAHtalog (Congenital Adrenal Hyperplasia: Patient and Clinical Outcomes in Real-World Practice Settings) Registry. The CAHtalog Registry is a U.S.-based CAH patient registry, or collection of clinical patient data, for patients with CAH due to 21-hydroxylase deficiency. The database was developed to support patient-centered clinical research to enhance the scientific community's foundational knowledge about CAH, and ultimately help patients who live with the condition. Patients consent to the inclusion of their data in the registry with CAH researchers primarily utilizing de-identified data. For more information about the CAHtalog Registry, please visit CAHtalog.com.

About the CAHtalyst® Studies
The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY® (crinecerfont) in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.

The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. 

The CAHtalyst Adult study included 182 adult patients 18 to 58 years of age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved.

Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing.

About CRENESSITY® (crinecerfont)
CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.

CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients 4 to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. 

Important Information

Approved Uses
CRENESSITY® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

IMPORTANT SAFETY INFORMATION

Do not take CRENESSITY if you:

Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.

CRENESSITY may cause serious side effects, including: 

Allergic reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.

Risk of Sudden Adrenal Insufficiency or Adrenal Crisis with Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.

Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.

The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.

These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information. 

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalog are registered trademarks of Neurocrine Biosciences, Inc.

Forward-Looking Statements 
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the interpretation and potential relevance of the data described in this press release, including the extent to which patient journey mapping may help healthcare professionals anticipate evolving needs among patients with classic congenital adrenal hyperplasia (CAH) and inform education, patient support and coordination across care teams; the potential benefits to be derived from CRENESSITY for the treatment of CAH; and the value and benefits CRENESSITY brings to patients with CAH. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release, which are based on records from a limited number of patients, are representative of the broader CAH patient population and whether patient journey mapping will help healthcare professionals anticipate evolving patient needs and inform education, patient support and coordination across care teams; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. 

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-CFT-US-0071 10/2026 

SOURCE Neurocrine Biosciences, Inc.

SummaryVICI has crashed despite higher cash flows and a new dividend hike.The market is pricing in the Caesars risk and higher rates.A recovery to $40 by 2030 may not be that far fetched.High Yield Landlord members get exclusive access to our real-world portfolio. See all our investments here » MicroStockHub/iStock via Getty Images

I last covered VICI Properties (VICI) in an article about a month ago explaining why I think that its recent crash is a buying opportunity.

Today, I want to go a step further and outline the math and reasoning why I

69.87K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of VICI; NNN; WPC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

CHICAGO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- TransUnion (NYSE: TRU) today announced that TIME has named its Branded Call Display solution one of the Best Inventions of 2026 in the Connectivity & Communication category. The solution helps consumers identify legitimate callers amid more than 50 billion robocalls initiated by fraudsters each year.

The solution was included in the Connectivity & Communications category, which honors the inventions that transform how people connect, communicate and collaborate. Branded Call Display enables businesses to display their name, logo and reason for the call. As a result, consumers can decide more accurately whether they should answer the phone.

“Rampant fraud has created a serious trust problem for the phone channel, to the point that consumers ignore important calls they’re expecting simply because they don’t recognize the number,” said James Garvert, Executive Vice President of Fraud and Communications Solutions at TransUnion. “Branded Call Display restores that trust for consumers and creates a new opportunity for businesses to promote and protect their brands.”

Branded Call Display authenticates calls in real time, helping protect consumers from spoofing and impersonation scams while improving engagement for legitimate businesses. Consumers instantly see who is calling, why they are calling, and whether the call is verified, transforming anonymous phone interactions into verified communications.

TransUnion also shaped the call-authentication ecosystem by supporting the establishment of STIR/SHAKEN as an industry standard and developing Branded Call Display to build on that infrastructure. Unlike traditional caller ID, which bad actors can spoof, or alternatives that require an app download, Branded Call Display operates through participating telecommunications networks.

Branded Call Display has demonstrated its value by collaborating with the largest mobile operators, growing business adoption and meaningful impact on operational results. Organizations across banking, healthcare, insurance and government agencies have reported various business benefits such as a 105% lift in answer rates, increases of up to 40% in callback rates, and 83% increase in offer conversions.

The solution has delivered more than 7 billion branded-call impressions across major wireless networks. In addition to the U.S., TransUnion has deployed Branded Call Display in Canada, Brazil and India, effectively impacting over 1B mobile subscribers.

TransUnion offers Branded Call Display through its Trusted Call Solutions suite, which helps reduce fraud and improve customer engagement. Learn more about these solutions here.

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments, we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.

The semiconductor industry has enjoyed a terrific run over the past four years, primarily driven by the artificial intelligence (AI) boom that has created incredible demand for chips in data centers.

The PHLX Semiconductor Sector Index has clocked a phenomenal jump of 440% over the past four years, easily crushing the tech-laden Nasdaq Composite index's 159% gain. However, chip stocks have been selling off lately. The PHLX Semiconductor Sector has lost more than 10% of its value in the past week.

Comments by the CEOs of Intel and Broadcom have contributed to the recent slide. Broadcom CEO Hock Tan believes that funding-related challenges could hinder the massive infrastructure investments fueling AI's expansion. Intel CEO Lip-Bu Tan is also concerned about capital-related constraints, noting that further investments in AI data center infrastructure could be influenced by the returns on investment this technology could deliver.

Not surprisingly, comments from two leading semiconductor companies have sent shockwaves through the industry. However, the correction in semiconductor stocks is an opportunity for savvy investors to buy a top name that could triple their money by 2030.

If you have $1,000 in investable cash after covering your expenses, paying off expensive loans, and saving enough for a rainy day, it would be a smart move to invest it in shares of Marvell Technology (MRVL -1.65%). Let's look at the reasons why.

Image source: Getty Images.

Marvell Technology is poised for phenomenal growth over the next five yearsThough the CEOs of Broadcom and Intel expressed concerns about the availability of capital to fund infrastructure expansion amid a high-interest-rate environment, they remained bullish about the state of AI. Broadcom's Tan, for example, pointed out that AI compute demand is outpacing supply, and he expects the supply constraints to persist through 2030.

MRVL Marvell Technology$241.24-$4.04 (-1.65%)

NASDAQ · As of 4:00 PM ET 10/15/26

Marvell Technology is gradually becoming a key player in the AI chip space. Though it trails Broadcom in the market for custom AI processors and networking chips, Marvell's recent investor day presentation makes it quite clear that it is going to make a big name for itself in the semiconductor industry.

The custom AI chips that Marvell manufactures help hyperscalers and AI companies lower operating costs. For instance, Microsoft claims that its latest custom AI chip is 40% more efficient compared to graphics processing unit (GPU)-based systems. Other estimates suggest that custom AI processors could reduce inference costs by 40% to 60% compared to GPUs.

Not surprisingly, Marvell anticipates a major acceleration in revenue growth over the next five years. The company reported $8.2 billion in revenue for fiscal 2026 (which ended on Jan. 31, 2026). Its top line increased by 42% from the prior year. However, Marvell sees its top line expanding at a compound annual growth rate (CAGR) of 55% to 60% through fiscal 2031. The company expects fiscal 2031 revenue to land between $70 billion and $90 billion after five years.

This terrific acceleration will be powered by the fast-growing demand for networking, switching, and storage components, as well as custom processors. What's more, Marvell's guidance indicates that it is poised to grow faster than the 35% CAGR in data center capital expenditure through 2030.

All in all, it is easy to see why analysts are estimating a major increase in Marvell's earnings per share over the next couple of years, following an estimated 48% jump in the current fiscal year.

MRVL EPS Estimates for Current Fiscal Year data by YCharts

Moreover, analysts have become quite bullish about Marvell's long-term growth prospects, which is why I think it is a good idea to invest $1,000 in this growth stock right now.

A $1,000 investment in this stock could be worth much more after five yearsWe saw in the previous chart that Marvell's earnings per share could reach $12.50 in fiscal 2029 (ending in January 2029). Analysts expect the company to maintain a solid long-term earnings growth rate and have increased their forecasts following its investor day earlier this month.

MRVL EPS LT Growth Estimates data by YCharts

Assuming Marvell's bottom line increases by 50% in fiscal years 2030 and 2031, its earnings per share could hit $28.12 after five years. If the stock trades at 31.5 times earnings at that time, in line with the Nasdaq-100 index's earnings multiple, its stock price could reach $885. That's 261% higher than Marvell's current stock price.

So, a $1,000 investment in this AI stock could be worth over $3,600 by the end of fiscal 2031 (which ends in January 2031 and overlaps with most of calendar 2030). That's why investors looking to add a top chip stock to their portfolios following the recent pullback in the sector should take a closer look at this name before it steps on the gas.

46 minutes ago

The Quantum Alliance, a consortium of nine crypto firms, was launched today. Publicly disclosed members include security company Hacken, Charles Hoskinson’s Midnight Foundation, quantum-resistant Layer 1 blockchain Quantus, and Postquant Labs; additional members have not yet been individually named. The alliance will develop common security standards for blockchains such as Bitcoin and Ethereum. It is estimated that roughly 6.4 million Bitcoin—representing 30.2% of the total supply—have exposed public keys, including around 1.1 million linked to Satoshi Nakamoto. Existing quantum computers are not yet capable of stealing these assets. However, the Quantum Alliance has significant internal divisions over the quantum threat timeline and response strategies. Bryn Bennett, chief revenue officer at The Vault, stated no one knows the exact date, but estimates of when quantum threats will become actionable are constantly advancing. Richard Carback, CTO of Postquant Labs, believes 2028 is a realistic timeline. The core debate centers on whether to freeze vulnerable assets. Carback advocates for transferring rather than freezing, while Bennett points out that freezing is a governance decision for the Bitcoin network, and any freeze would set a precedent that trades property rights and network neutrality for quantum risk. Previously, CZ suggested freezing Satoshi’s Bitcoin, and developer Jameson Lopp also proposed restricting vulnerable tokens, though critics argue this violates Bitcoin’s fundamental promise of non-seizure. Moving forward, the alliance plans to publish joint security testing and migration guidelines.

Scan the QR code

Download APP